Abiopharma

🔍 ORDAN MARK S (Director)

Company: Carlyle Group Inc. (CG)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 4,450 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 26,163.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 4,450 shares of Common Stock at $49.44 per share (Direct)
  Date: 2026-05-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 30,613.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: These securities are a restricted stock unit award granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities will vest on May 1, 2027, subject to the reporting person's continued service on the Board of Directors of The Carlyle Group Inc. on such vesting date.
• F2: These securities are shares of the Issuer's common stock granted under The Carlyle Group Inc. Amended & Restated 2012 Equity Incentive Plan. These securities are vested upon grant pursuant to an election made by the reporting person to receive shares of the Issuer's common stock in lieu of the reporting person's annual cash retainers for service on the Issuer's Board of Directors.